Teva Reports Second Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Teva Pharma (TEVA) Tops Q2 EPS by 14c; Raises Outlook
August 2, 2018 7:02 AM EDTTeva Pharma (NYSE: TEVA) reported Q2 EPS of $0.78, $0.14 better than the analyst estimate of $0.64. Revenue for the quarter came in at $4.7 billion versus the consensus estimate of $4.74 billion.
GUIDANCE:
Teva Pharma sees FY2018 EPS of $2.55-$2.80, from $2.40-$2.65 and... More
